Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $37.48
Key levels
Resistance$37.48
Support$28.80
Support$24.15
Latest news & SEC filings
AnalystBTIG Reiterates Buy Rating on Alto Neuroscience With $37 Price Target
EarningsAlto Neuroscience Posts Q3 2026 Financials
EarningsAlto Neuroscience posts smaller Q3 loss than expected
All ANRO news →Alto Neuroscience is a clinical-stage biopharmaceutical company developing precision treatments for psychiatric conditions. Its pipeline targets major depressive disorder, bipolar disorder, and schizophrenia, and some candidates pair a therapeutic with a delivery device. The company uses a biomarker-based platform to match patients with treatments and is working on diagnostic tools. It operates in the United States and may run trials in other countries.
Based on the company's 10-K filed Mar 16, 2026.
NYSE · Healthcare
SEPT Low Target
$26.00
SEPT Mid Target
$40.50
SEPT High Target
$60.00
Analyst Consensus
$40.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ANRO.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$33.69
12
Moat Score
NONE
2/9
Piotroski Score
11.3
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Smith Nicholas Conrad | officer | Buy | 55,000 | $128K | Oct 2, 2026 |
| Smith Nicholas Conrad | officer | Buy | 24,056 | $57K | Sep 30, 2026 |
| Smith Nicholas Conrad | officer | Sale | 23,170 | $597K | Sep 30, 2026 |
| Smith Nicholas Conrad | officer | Sale | 886 | $24K | Sep 30, 2026 |
| Smith Nicholas Conrad | officer | Buy | 56,455 | $133K | Sep 29, 2026 |
| Smith Nicholas Conrad | officer | Buy | 54,375 | $128K | Sep 29, 2026 |
| Smith Nicholas Conrad | officer | Sale | 110,830 | $2.9M | Sep 29, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
12.4%
FCF Growth YoY
-4.6%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for ANRO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:25 | $31.15 | 7,581 | $$236K | SELL |
| 20:59:05 | $31.03 | 2,600 | $$81K | MIDPOINT |
| 20:58:31 | $31.01 | 1,313 | $$41K | BUY |
| 20:58:31 | $31.02 | 1,313 | $$41K | SELL |
| 20:57:52 | $31.06 | 7,000 | $$217K | BUY |
5 dark pool trades shown · $$616K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Alto Neuroscience, Inc. (ANRO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Alto Neuroscience, Inc. (ANRO) is at $31.15, up 8.88% (+$2.54) at the Nov 11, 2026 close.
Latest ANRO news — Nov 11, 2026: BTIG Reiterates Buy Rating on Alto Neuroscience With $37 Price Target · Nov 10, 2026: Alto Neuroscience Posts Q3 2026 Financials
The average analyst price target for ANRO is $40.50, ranging from $26 to $60, based on 6 analysts. Latest: HC Wainwright & Co. maintains on Oct 19, 2026.
Analyst ratings for ANRO: 0 Buy, 12 Hold, 0 Sell — consensus Hold.
ANRO last reported on Aug 12, 2026: EPS -$0.65 vs -$0.73 expected — a beat of 11.5%.
ANRO does not currently pay a dividend.
Support: $28.80, $24.15, $21.50. Resistance: $37.48.
Insider activity: NEUTRAL, 0 buys and 3 sells in the last 90 days.
Nov 11, 2026: BTIG Reiterates Buy Rating on Alto Neuroscience With $37 Price Target · Nov 10, 2026: Alto Neuroscience Posts Q3 2026 Financials · Nov 10, 2026: Alto Neuroscience posts smaller Q3 loss than expected